What's Happening?
A recent clinical trial has demonstrated that oral semaglutide, a medication traditionally administered via injection under brand names like Wegovy and Ozempic, is effective for weight loss. The trial involved 205 participants receiving semaglutide and 102 receiving a placebo, alongside diet and exercise counseling over 71 weeks. The results showed a significant average weight loss in the semaglutide group, with a mean reduction in body weight of 13.6 percent. The study also noted improvements in physical function and metabolic health markers. The oral form of semaglutide could offer a more accessible option for patients who are averse to injections.
Why It's Important?
The development of an oral form of semaglutide could significantly impact the treatment of obesity and diabetes. By eliminating the need for injections, the medication becomes more accessible, particularly in regions where refrigeration for injectable drugs is a barrier. This could broaden the reach of obesity care and potentially improve adherence to treatment. The trial's findings suggest that oral semaglutide could be a viable alternative for those who prefer not to use injectable medications, potentially increasing the number of individuals who can benefit from this treatment.
What's Next?
Novo Nordisk, the company behind the trial, is seeking regulatory approval to market Ozempic in tablet form. If approved, the oral medication could soon be available, providing a new option for weight management. The company and healthcare providers will likely monitor the long-term effects and potential side effects of the oral medication as it becomes more widely used.
